13 WTHR - Indianapolis News |Affymax 3Q loss narrows partnership payments

Affymax 3Q loss narrows partnership payments

Posted: Updated:

PALO ALTO, Calif. (AP) - Biotechnology company Affymax Inc. said Wednesday its third-quarter loss narrowed on a boost in payments from its partner Takeda Pharmaceutical on the anemia drug candidate Hematide.

The company lost $18.4 million, or 97 cents per share, compared with a loss of $26.2 million, or $1.72 per share, during the same period a year earlier. Revenue rose 35 percent to $29.2 million from $21.6 million, boosted by its development partnership for Hematide.

Analysts polled by Thomson Reuters expected a loss of $1.23 per share on revenue of $26.1 million.

Operating expenses fell slightly to $47.9 million from $48.1 million.

Affymax has said it plans to ask for Food and Drug Administration approval for Hematide in 2010.

Shares of Affymax fell 2 cents to $20.65 in morning trading.

Copyright 2009 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Powered by WorldNow
All content © Copyright 2002 - 2010 WorldNow and WTHR. All Rights Reserved.
For more information on this site, please read our Privacy Policy and Terms of Service.It is the policy of The Dispatch Broadcast Group to provide equal employment opportunity to all qualified individuals without regard to their race, color, religion, national origin, age, sex, marital status, disability, military status, citizenship or any other legally-protected status in accordance with applicable local, state and federal law. Jobs at WTHR EEO Public File Report